Biogen’s Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over

Sanofi Alum Is New Addition To Executive Committee

Recently appointed head of corporate development in an ongoing leadership shakeup, Keeney is helping to shape Biogen’s sustainable growth strategy in neuroscience and beyond. 

Biogen Inc. HQ in Cambridge, MA
Biogen leadership has changed significantly in recent months • Source: Shutterstock

Biogen, Inc.’s new president and CEO Christopher Viehbacher has brought in former Sanofi colleague Adam Keeney to help advance the company’s goal of “sustainable growth” from its existing products and programs as well as from assets sourced externally. Keeney, Biogen’s newly appointed executive vice president and head of corporate development, told Scrip he is encouraged by what the company already is working on and is looking forward to bringing novel therapies into the mix.

But to say that Biogen’s current growth trajectory is in need of a turnaround may be an understatement. The company...

More from Deals

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By 

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

More from Business